Cryptococcal disease and HIV infection

Bibliography

• MOCROFT A. LEDERGERBER B, KATLAMA G et al.: Decline in the AIDS and death rates in the EuroSIDA study: an observational cohort. Lancet (2003) 362:22–29.
   Google Scholar
• KAPLAN JE, HANSON D, DWORKIN MS et al.: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infra. Dis. (2000) 30:S5–S14.
   Web of Science ®Google Scholar
• MOCROFT A, SABIN CA, YOULE M et al.: Changes in AIDS-defining illnesses in a London Clinic, 1987–1998.1 Acquir. Immune Defic. Syndr. (1999) 21:401–407.
   Google Scholar
• KAPLAN JE, HANSON D, DWORKIN MS et al.: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infra. Dis. (2000) 30:S5S14.
   Web of Science ®Google Scholar
• NEUENBURG JK, BRODT HR, HERNDIER BG et al.: HIV-related neuropathology, 198599: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2002) 31:171–177.
   PubMed Web of Science ®Google Scholar
• FRANZOT SP, SALKIN IF, CASADAVELL A et al.: Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J. Clin. Microbiol (1999) 37:838–840.
   Google Scholar
• TRESELER CB, SUGAR AM: Fungal meningitis. Infect. Dis. Clin. North Am. (1990) 4:789–808.
   PubMedGoogle Scholar
• ABADI J, NACHMAN S, KRESSEL AB, PIROFSKI A: Cryptococcosis in children with AIDS. Clin. Infect. Dis. (1999) 28:309–313.
   PubMed Web of Science ®Google Scholar
• DISMUKES WE: Cryptococcal meningitisin patients with AIDS. J. Infect. Dis. (1988) 157:624–628.
   PubMed Web of Science ®Google Scholar
• KAPLAN, MICHELET C, ARVIEUX C, FRANCOIS C et al.: Opportunistic infections occurring during highly active antiretroviral treatment. AIDS (1998) 12:1815–1822.
   PubMed Web of Science ®Google Scholar
• SERRAINO D, PURO V, BOUMIS E et al.: Epidemiological aspects of major opportunistic infections of the respiratory tract in persons with AIDS: Europe, 1993-2000. AIDS (2003) 17:2109–2116.
   PubMed Web of Science ®Google Scholar
• MIRZA SA, PHELAN M, RIMLAND D et al.: The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin. Infect. Dis. (2003) 36:789–794.
   PubMed Web of Science ®Google Scholar
• DROMER F, MATHOULIN-PELISSIER S,FONTANET A et al: Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre-and post-HAART eras. AIDS (2004) 18:555–562.
   PubMed Web of Science ®Google Scholar
• ••References [12] and [13] discuss changes in cryptococcal disease in the highly active antiretroviral era.
   Google Scholar
• DIAMOND RD: Cryptococcus neoformans. In: Mandell Douglas and Bennett 's Principles and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin R (Eds) New York, Churchill Livingstone (1995) 4:2331–2340.
   Google Scholar
• CHUCK SL, SANDE MA: Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl. J. Med. (1989) 21:794–799.
   Google Scholar
• ••Evidence to support the authors' finalstatement that many practitioners feel the addition of flucytosine to amphotericin is unnecessary.
   Google Scholar
• WARKENTINE F, HINTHORN D, PANTAZIS C, LUCHI M: Primary Pulmonary Cryptococcosis presenting as a solitary nodule in a patient with AIDS. Infect. Med. (2000)17(12):802–805.
   Google Scholar
• DURDEN FM, ELEWSKI B: Cutaneous involvement with Cryptococcus neoformans in AIDS. J. Am. Acad. Dermatol (1994) 30:844–848.
   PubMed Web of Science ®Google Scholar
• KHANNA N, CHANDRAMUKI A. DESAI A et al.: Cryptococcal infections of the central nervous system: an analysis of predisposing factors, laboratory findings and outcome in patients from South India with special reference to HIV infection. J. Med. Microbiol (1996) 45:376–379.
   Google Scholar
• KWARTLER JA, LINTHICUM FH, JAI-IN AF et al.: Sudden hearing loss due to AIDS-related cryptococcal meningitis - a temporal bone study. Otolaryngol Head Neck Surg. (1991) 104:265–269.
   PubMed Web of Science ®Google Scholar
• LIPSON BK, FREEMAN WR, BENIZ J et al.: Optic neuropathy associated with cryptococcal arachnoiditis in AIDS patients. Am. J. Ophthalmol. (1989) 107:523–527.
   PubMed Web of Science ®Google Scholar
• REX JH, LARSEN RA, DISMUKES WE, CLOUD GA, BENNETT JE: Catastrophic visual loss due to cryptococcus neoformans meningitis. Medicine (1993) 72:207–224.
   PubMed Web of Science ®Google Scholar
• SAAG MS, GRAYBILL RJ, LARSEN et al.: Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. (2000) 30:710–718.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive guidelines on the management of cryptococcal disease.
   Google Scholar
• NEWTON PN, LH THAI, TIP NQ et al.: A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin. Infect. Dis. (2002) 35:769–772.
   PubMed Web of Science ®Google Scholar
• TANG LM: Ventriculo-peritoneal shunt in cryptococcal meningitis with hydrocephalus. Surg. NeuroL (1990) 33:314–319.
   PubMedGoogle Scholar
• VISNEGARWALA F, GRAVISS EA, LACKE CE et al.: Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin. Infect. Dis. (1998) 27(5):1231–1237.
   PubMed Web of Science ®Google Scholar
• POWDERLY WG, CLOUD GA, DISMUKES WE, SAAG MS: Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. (1994) 18(5):789–792.
   PubMed Web of Science ®Google Scholar
• NELSON MR, BOWER M, SMITH D et al.: The value of serum cryptococcal antigen in the diagnosis of cryptococcal infection in patients infected with the human immunodeficiency virus. J. Infect. (1990) 21(2):175–181.
   PubMed Web of Science ®Google Scholar
• VAN DER HORST C, SAAG M, CLOUD G et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl. J. Med. (1997) 337:15–21.
   Google Scholar
• ••Evidence to support the authors' finalstatement that many practitioners feel the addition of flucytosine to amphotericin is unnecessary.
   Google Scholar
• SAAG MS, POWDERLY WG, CLOUD GA: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl. J. Med. (1992) 326:83–89.
   PubMed Web of Science ®Google Scholar
• DUNBAR SA, EASON RA, MUSHER DM et al.: Microscopic examination and broth culture of cerebrospinal fluid in diagnosis of meningitis. J. Clin. Microbiol (1998) 36:1617–1620.
   PubMed Web of Science ®Google Scholar
• POPOVICH MJ, ARTHUR RH, HELMER E: CT of intracranial cryptococcosis. Am. J. Neuroradiol (1990) 11:139–142.
   PubMed Web of Science ®Google Scholar
• MISZKIEL KA, HALL-CRAGGS MA, MILLER RF et al.: The spectrum of MRI findings in CNS cryptococcosis in AIDS. Clin. Redid. (1996) 51:842–850.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH, WALSH TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. (1996) 40:270–291.
   Web of Science ®Google Scholar
• PELEG AY, WOODS ML: Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J. Antimicrob. Chemother. (2004) 54(4):803–808.
   PubMed Web of Science ®Google Scholar
• •Strategies to reduce toxicity.
   Google Scholar
• SHOHAM S, WALSH TJ: Lipid Formulations of Amphotericin B: current roles in management of invasive fungal infections. Curr. Treatment Options Infect. Dis. (2002) 4:535–547.
   Google Scholar
• COKER RJ, VIVIANI M, GAZZARD BG et al.: Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS (1993) 7(6):829–835.
   PubMed Web of Science ®Google Scholar
• LEENDERS AC, REISS P, PORTEGIES P et al.: Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated crytpococcal meningitis. AIDS (1997) 11(3):146–171.
   Google Scholar
• SHARKEY PK, GRAYBILL JR, JOHNSON ES: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1996) 22:315–321.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH, WALSH TJ: Antifitngal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. (1996) 40:270–291.
   Web of Science ®Google Scholar
• ANDRIOLE V: Current and future antifungal therapy: new targets for antifungal agents. J. Antimicrob. Chemother. (1999) 44:151–162.
   PubMed Web of Science ®Google Scholar
• GROLL AH, PISCITELLI SC, WALSH TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol (1998) 44:343–500.
   PubMedGoogle Scholar
• PFALLER MA, ZHANG J, MESSER SA et al.: In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antiomicrob. Agents Chemother. (1999) 43(1):169–171.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ S, D MILATOVIC, THIEL E: Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br. J. Hematol (1997) 97:663–665.
   PubMed Web of Science ®Google Scholar
• PEARSON MM: Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. (2003) 37(3):420–432.
   PubMed Web of Science ®Google Scholar
• •New agents in the treatment of cryptococcal disease.
   Google Scholar
• SAROSI GA, PARKER JD, DOTO IL, TOSH FE: Amphotericin Bin cryptococcal meningitis. Long-term results of treatment. Ann. Intern. Med. (1969) 71:1079–1087.
   PubMed Web of Science ®Google Scholar
• HAMILL R: Cryptococcal meningitis. Curr. Treat. Opt. Inf Dis. (2001) 3:129–136.
   Google Scholar
• BENNETT JE, DISMUKES WE, DUMA RJ et al.: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl. J. Med. (1979) 301:126–131.
   PubMed Web of Science ®Google Scholar
• DISMUKES WE, CLOUD G, GALLIS HA et al.: Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N EngL J. Med. (1987) 317:334–341
   PubMed Web of Science ®Google Scholar
• BROUWER AE, RAJANUWONG A, CHIERAKUL W et al.: Combination antifungal theraoy for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 363(9423):1764–1768.
   PubMed Web of Science ®Google Scholar
• BERG J, CLANCY CJ, NGUYEN MH: The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin. Infect. Dis. (1998) 26:186–187.
   PubMed Web of Science ®Google Scholar
• DE LALLA F, PELLIZZER G, VAGLIA A et al.: Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period. Clin. Infect. Dis. (1995) 20:263–266.
   PubMed Web of Science ®Google Scholar
• MAYANJA KH, OISHI K, MITARAI S et al.: Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin. Inf Dis. (1998) 26(61:1362–1366.
   PubMedGoogle Scholar
• LARSEN RA, BOZZETTE SA, JONES BE et al.: Fluconazole combined with flucytosine for the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1994) 19:741–745.
   PubMed Web of Science ®Google Scholar
• MOOTSIKAPUN P, SMITHARITHEE R, CHETCHOTISAKID P: Randomised open labeled comparative study between amphotericin B plus fluconazole versus amphotericin B plus itraconazole versus amphotericin B alone for treatment of cryptococcal meningitis in AIDS. 15th International AIDS Conference, Bangkok (2004) MPeB3232.
   Google Scholar
• NELSON MR, FISHER M, CARTLEDGE J, ROGERS T, GAZZARD BG: The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS (1994) 8(5):651–654.
   PubMed Web of Science ®Google Scholar
• KELLY SL, LAMB DC, TAYLOR M, CORRAN AJ, BALDWIN BC, POWDERLY WG: Resistance to amphotericin B associated with defective sterol delta 8- 7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS MicrobioL Lett. (1994) 122:39–42.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, SOBEL J, SAAG M et al.: Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin. Infect. Dis. (2000) 30:47–54.
   PubMed Web of Science ®Google Scholar
• GARCIA-GONZALES V, LOPEZ-ROMERO C, LAMAS-BOJORQUEZ C et aL: Management of intracranial hypertension in patients with meningeal cryptococcosis and AIDS: Repetitive lumbar punctures versus dexamethasone. 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco (2001) 760.
   Google Scholar
• FESSLER RD, SOBEL J, GUYOT L et al.: Management of elevated intracranial pressure in patients with cryptococcal meningitis. J. AIDS (1998) 17(2):137–142.
   Web of Science ®Google Scholar
• RICHARDSON MD, WARNOCK DW: Fungal Infection, 2nd edn. Blackwell Science (1997):149–159.
   Google Scholar
• SHELBURNE SA III, DARCOURT J, WHITE AC JR et al.: The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin. Infect. Dis. (2005) 40(7):1049–1052.
   Google Scholar
• PAPPAS PG, BUSTAMANTE B, TICONA E et al.: Adjunctive interferon gamma (IFN-gamma) for treatment of cryptococcal meningitis (crypto): a randomized, double-blind pilot trial. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago (2001) LB–10.
   Google Scholar
• MILLER JL, SCHELL WA, WILLS EA et al.: In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. (2004) 48(2):384–387.
   PubMed Web of Science ®Google Scholar
• RIMAROLI C, BRUZZESE T: In vitro activity of a new polyene, SPA-S-843, against yeasts. Antimicrob. Agents Chemother. (1998) 42:3012–3013.
   PubMed Web of Science ®Google Scholar
• USPHS/IDSA PREVENTION OF OPPORTUNISTIC INFECTIONS WORKING GROUP: 2002 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Morb. Mortal. Wkly Rep. (2002) 51(RR 08):1–46.
   Google Scholar
• POWDERLY WG, FINKELSTEIN D, FEINBERG J et al.: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N EngL J. Med. (1995) 332:700–705.
   PubMed Web of Science ®Google Scholar
• SINGH, N, BARNISH, M J, BERMAN S et al.: Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of 100/mm3: demonstration of efficacy in a prospective, multicenter trial. Clin. Infect. Dis. (1996) 23:1282–1286.
   PubMed Web of Science ®Google Scholar
• JOHN L, NELSON MR: Primary prophylaxis for cryptococcal meningitis. HIV Med (2004)5(3):131–132.
   PubMed Web of Science ®Google Scholar
• CHETCHOTISAKD SUNGKANUPARPH S, THINKHAMROP B, MOOTSIKAPUN BOONYAPRWIT P: A multicentre, randomised, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immunodeficiency. HIV Med. (2004) 5(3):139–142.
   Web of Science ®Google Scholar
• POWDERLY WG, SAAG MS, CLOUD GA et al.: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N EngL J. Med. (1992) 326:793–798.
   PubMed Web of Science ®Google Scholar
• BOZZETTE SA, LARSEN RA, CHIU J et al.: A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis inthe acquired immunodeficiency syndrome. N EngL J. Med. (1991) 324:580–584.
   PubMed Web of Science ®Google Scholar
• SAAG MS, CLOUD GC, GRAYBILL JR et aL: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. (1999) 28:291–296.
   PubMed Web of Science ®Google Scholar
• NWOKOLO N, FISHER M, GAZZARD BG, NELSON MR: Cessation of secondary prophylaxis in patients with cryptococcosis. AIDS (2001) 15(11):1438–1439.
   PubMed Web of Science ®Google Scholar
• ABERG JA, PRICE RW, HEEREN DM, BREDT B: A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J. Infect. Dis. (2002) 185(8):1179–1182.
   PubMed Web of Science ®Google Scholar
• ROLLOT F, BOSSI P, TUBIANA R, CAUMES E, ZELLER V, KATLAMA C, BRICAIRE F: Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy. AIDS (2001) 15(11):1448–1449.
   PubMed Web of Science ®Google Scholar
• MARTINEZ E, GARCIA-VIEJO MA, MARCOS MA et al.: Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS (2000) 14(16):2615–2617.
   PubMed Web of Science ®Google Scholar
• MUSSINI C, PEZZOTTI P, MIRO JM et al.: Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin. Infect. Dis. (2004) 38:565–571.
   PubMed Web of Science ®Google Scholar
• ••Discontinuation of prophylaxis — an important issue.
   Google Scholar